Actavis Settles Patent Litigation Related To Its Generic Version Of Acanya

(RTTNews) - Actavis plc (ACT) announced it has entered into an agreement with Valeant Pharmaceuticals International (VRX.TO, VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Valeant will grant Actavis a license to market its generic Acanya Gel beginning in July 1, 2018 or earlier under certain circumstances. Other details of the settlement were not disclosed.

Acanya Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Launch of Actavis' product is contingent upon Actavis receiving final approval from the U.S. FDA on its Abbreviated New Drug Application for generic Acanya Gel.